VenatoRx Pharmaceuticals
PrivateLast Round
Grant
Oct 10, 2023
Total Funding Raised
$329.5M
Company Overview
VenatoRx Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of novel anti-infective agents to treat multi-drug-resistant bacterial and viral infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VenatoRx Pharmaceuticals Comparables
Compare VenatoRx Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Allecra Therapeutics | 90% | |
| Antabio | 87% | |
| Fedora Pharmaceuticals Inc. | 85% |
VenatoRx Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Oct 10, 2023 | ||||
| VC Round | Dec 1, 2022 | ||||
| Grant | Oct 3, 2022 | ||||
| Series C | Apr 4, 2022 | ||||
| Grant | Jul 27, 2020 | ||||
Grant | Nov 25, 2019 |
VenatoRx Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMR Action Fund | Series C |
| National Institute of Allergy and Infectious Diseases | Grant |
| CARB-X | Grant |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Foresite Capital | Series B |
| Versant Ventures | Series B |
| Abingworth | Series B, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 10, 2023
$167M grant awarded by BARDA and PHEMCE.
- Oct 3, 2022
$319M grant awarded by BARDA and PEMCE.
VenatoRx Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about VenatoRx Pharmaceuticals's valuation, stock price, and market status.
Is VenatoRx a public or private company?
VenatoRx is a private company.
What is the current stock price of VenatoRx?
VenatoRx is a private company with no public stock price. No recent secondary market data is available.
How much is VenatoRx worth (valuation)?
Valuation information for VenatoRx is not publicly available.
Can I buy VenatoRx stock?
VenatoRx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was VenatoRx's last funding round?
VenatoRx's most recent funding round was Grant on October 10, 2023.
Who are the main investors in VenatoRx?
Key investors in VenatoRx include AMR Action Fund, Versant Ventures.
Will VenatoRx IPO soon?
No public IPO plans have been announced for VenatoRx.
How can I track VenatoRx secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VenatoRx's secondary market activity and sign up for updates.